Biotech entity
All 1 tracked stories fall under one category: pharma. IAMGOLD is most often covered alongside AtriCure, which appears in 1 of these 1 story. IAMGOLD appears in 1 tracked Biotech story from February 18, 2026. The tracked stories average 6 original sources each.
Last mentioned: Feb 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. IAMGOLD is most often covered alongside AtriCure, which appears in 1 of these 1 story. IAMGOLD appears in 1 tracked Biotech story from February 18, 2026. The tracked stories average 6 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering IAMGOLD. Shared-story counts are live from our verified record — not editorial picks.
Insulet and AtriCure reported strong quarterly results, both beating analyst estimates on top and bottom lines. These results highlight robust demand for insulin delivery systems and atrial fibrillation treatments despite broader macroeconomic pressures.
Source: Seeking Alpha · Seeking Alpha
IAMGOLD is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
